Predicting Drug Exposure During Pregnancy Using PBPK Models
This webinar described how the Simcyp pregnancy-PBPK model was used to predict systemic exposure during pregnancy for two probe medications: tacrolimus and oseltamivir.
Month: March 2017
Pharmacokinetic Modeling and Simulations of Human Anti-C1s Antibody (TNT009) in Normal Human Volunteers and Patients with Complement-mediated Disorders
Pharmacokinetic/Pharmacodynamic Analysis of Human Anti-C1s Antibody (TNT009) and Classical Complement Pathway (CP) Activity
Population Pharmacokinetic Modeling of Teduglutide to Support Dosing in Pediatric Patients with Short Bowel Syndrome
Certara Scientists Showcase PK/PD Modeling Advances at ASCPT Annual Meeting
PRINCETON, NJ – Mar. 13, 2017 – Certara today announced that its scientists will be highlighting pharmacokinetic (PK) and pharmacodynamic (PD) modeling advances during 19 sessions at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2017 Annual Meeting.
Changing the Game in Drug Development: Certara 最佳博客精选
A selection of short essays from our blog containing insights from our thought leaders on how modeling and simulation has impacted and is continuing to reshape our approach to drug development.
Accelerating the Pace of Generic Pharmaceutical Development
The formulation team at Impax Laboratories leveraged Certara’s IVIVC Toolkit for Phoenix WinNonlin to optimize generic formulations.
Certara Launches Simcyp Access to Expand Simulator Availability
PRINCETON, NJ – Mar. 9, 2017 – Certara today announced the launch of Simcyp Access, a new cloud-based licensing approach that provides trained individuals at smaller pharmaceutical companies (less than 500 employees) with a method for using Certara’s Simcyp Population-based Simulator in research projects.
The Model-informed Precision Dosing Revolution Is Coming
Modeling and simulation (M&S) has been widely accepted and adopted by biopharmaceutical companies and global regulatory agencies. However, its implementation in clinical care has been modest to date. Model-based approaches are essential to realize the goal of precision dosing—providing the right drug dose to maximize therapeutic benefit, while reducing risk for each individual patient. The … Continued
